Nov 13th, 2020

GALACTIC-HF results

Investigator John Teerlink, MD, FAHA, summarizes the results of GALACTIC-HF.

Investigator John Teerlink, MD, FAHA, summarizes the results of GALACTIC-HF, which found that improving cardiac function with omecamtiv mecarbil significantly reduced the risk of a first heart failure event or cardiac death in patients with heart failure with reduced ejection fraction.

audience

Early ablation bests medication in treatment naïve AFib patients

audience shot

First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension

audience shot

Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD

LBS 05 panelists

Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression

audience shot

Bivalirudin superior to unfractionated heparin in primary PCI following STEMI

Panelists of the Mindful Disruption panel

Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD

Person putting on tennis shows

Join the Wellness Challenge at #AHA22

Scientific Sessions attendees in lobby

Join us for Scientific Sessions 2022 in Chicago or online

Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD

Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption

Lbs02 Group Blood Patel

Update on local and global hypertension science

(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA

Late-Breaking Science: New information in cardiac disease

(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA

The latest science in heart failure